Extracellular vesicles (EVs) are nanoparticles secreted by all cells, enriched in proteins, lipids, and nucleic acids related to cell-to-cell communication and vital components of cell-based therapies. Mesenchymal stromal cell (MSC)-derived EVs have been studied as an alternative for osteoarthritis (OA) treatment. However, their clinical translation is hindered by industrial and regulatory challenges. In contrast, platelet-derived EVs might reach clinics faster since platelet concentrates, such as platelet lysates (PL), are already used in therapeutics. Hence, we aimed to test the therapeutic potential of PL-derived extracellular vesicles (pEVs) as a new treatment for OA, which is a degenerative joint disease of articular cartilage and does not have any curative or regenerative treatment, by comparing its effects to those of human umbilical cord MSC-derived EVs (cEVs) on an ex vivo OA-induced model using human cartilage explants.

中文翻译：

---

使用离体炎症骨关节炎模型比较血小板和间充质基质细胞来源的细胞外囊泡对人软骨外植体的影响。

细胞外囊泡 (EV) 是所有细胞分泌的纳米颗粒，富含与细胞间通讯相关的蛋白质、脂质和核酸以及细胞疗法的重要组成部分。间充质基质细胞 (MSC) 衍生的 EV 已被研究作为骨关节炎 (OA) 治疗的替代方案。然而，它们的临床转化受到工业和监管挑战的阻碍。相比之下，血小板衍生的 EV 可能会更快地到达诊所，因为血小板浓缩物，例如血小板裂解物 (PL)，已经用于治疗。因此，我们的目的是测试 PL 衍生的细胞外囊泡 (pEV) 作为 OA 新疗法的治疗潜力，OA 是一种关节软骨退行性关节疾病，没有任何治愈或再生治疗方法，通过比较其效果使用人软骨外植体在离体 OA 诱导模型上培养人脐带 MSC 衍生的 EV (cEV)。